Company intelligence / Profile preview
Hansa Biopharma
Lund, Swedenhansabiopharma.com ↗
- Ownership
- Public · HNSA
- Employees
- ~200
- Development stage
- Commercial
01
Overview
Hansa Biopharma has achieved significant milestones with its first-generation enzyme, imlifidase, approved in the EU for desensitization in kidney transplantation. The company is advancing its next-generation enzyme, HNSA-5487, and expanding into autoimmune diseases and gene therapy.
- Therapeutic areas
- OncologyImmunologyRare DiseasesNephrology
- Modalities
- Enzyme
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sarepta TherapeuticsAskBio
04
Financials
- Market cap
- $399.2M
- Total revenue
- $22.5M
- Enterprise value
- $447.9M
Beyond the preview
Go deeper on Hansa Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hansa Biopharma.